Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2015 Feb;148(2):344-54.e5; quiz e14-5.
doi: 10.1053/j.gastro.2014.10.011. Epub 2014 Oct 16.
Affiliations
- PMID: 25448924
- DOI: 10.1053/j.gastro.2014.10.011
Meta-Analysis
Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis
Glen S Hazlewood et al. Gastroenterology. 2015 Feb.
Abstract
Background & aims: There is controversy regarding the best treatment for patients with Crohn's disease because of the lack of direct comparative trials. We compared therapies for induction and maintenance of remission in patients with Crohn's disease, based on direct and indirect evidence.
Methods: We performed systematic reviews of MEDLINE, EMBASE, and Cochrane Central databases, through June 2014. We identified randomized controlled trials (N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, vedolizumab, or combined therapies with placebo or an active agent for induction and maintenance of remission in adult patients with Crohn's disease. Pairwise treatment effects were estimated through a Bayesian random-effects network meta-analysis and reported as odds ratios (OR) with a 95% credible interval (CrI).
Results: Infliximab, the combination of infliximab and azathioprine (infliximab + azathioprine), adalimumab, and vedolizumab were superior to placebo for induction of remission. In pair-wise comparisons of anti-tumor necrosis factor agents, infliximab + azathioprine (OR, 3.1; 95% CrI, 1.4-7.7) and adalimumab (OR, 2.1; 95% CrI, 1.0-4.6) were superior to certolizumab for induction of remission. All treatments were superior to placebo for maintaining remission, except for the combination of infliximab and methotrexate. Adalimumab, infliximab, and infliximab + azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1), infliximab (OR, 1.6; 95% CrI, 1.0-2.5), infliximab + azathioprine (OR, 3.0; 95% CrI, 1.7-5.5) for maintenance of remission. Adalimumab and infliximab + azathioprine were superior to certolizumab: adalimumab (OR, 2.5; 95% CrI, 1.4-4.6) and infliximab + azathioprine (OR, 2.6; 95% CrI, 1.3-6.0). Adalimumab was superior to vedolizumab (OR, 2.4; 95% CrI, 1.2-4.6).
Conclusions: Based on a network meta-analysis, adalimumab and infliximab + azathioprine are the most effective therapies for induction and maintenance of remission of Crohn's disease.
Keywords: Anti-TNF Therapy; IBD; Immunosuppressive Agents; Network Meta-analysis.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
- In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution.
Bonovas S, Moja L, Danese S. Bonovas S, et al. Gastroenterology. 2015 Jun;148(7):1483-4. doi: 10.1053/j.gastro.2015.02.058. Epub 2015 Apr 30. Gastroenterology. 2015. PMID: 25935528 No abstract available. - Reply: To PMID 25448924.
Hazlewood GS, Rezaie A, Kaplan GG. Hazlewood GS, et al. Gastroenterology. 2015 Jun;148(7):1484. doi: 10.1053/j.gastro.2015.04.042. Epub 2015 Apr 30. Gastroenterology. 2015. PMID: 25935530 No abstract available.
Similar articles
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Singh S, et al. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34688373 Free PMC article. - Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW, Bickston SJ. Behm BW, et al. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Cochrane Database Syst Rev. 2008. PMID: 18254120 Review. - Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Cholapranee A, et al. Aliment Pharmacol Ther. 2017 May;45(10):1291-1302. doi: 10.1111/apt.14030. Epub 2017 Mar 22. Aliment Pharmacol Ther. 2017. PMID: 28326566 Free PMC article. Review. - Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. McDonald JW, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235598 Updated. Review.
Cited by
- Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
Na JE, Park YE, Park J, Kim TO, Lee JH, Park SB, Kim S, Lee SB; Busan Ulsan Gyeongnam Intestinal Study Group Society (BIGS). Na JE, et al. BMC Gastroenterol. 2024 Sep 11;24(1):306. doi: 10.1186/s12876-024-03403-8. BMC Gastroenterol. 2024. PMID: 39261766 Free PMC article. - Global geoepidemiology of gastrointestinal surgery rates in Crohn's disease.
Weissman S, Aziz M, Bangolo A, Nagesh VK, Aung H, Mathew M, Garcia L, Chandar SA, Karamthoti P, Bawa H, Alshimari A, Kejela Y, Mehdi N, Joseph CA, Kodali A, Kumar R, Goyal P, Satheesha S, Nivedita F, Tesoro N, Sethi T, Singh G, Belal A, Intisar A, Khalid H, Cornwell S, Suresh SB, Ahmed K, Marole KK, Anand OP, Reshi RB, Mehta TI, Elias S, Feuerstein JD. Weissman S, et al. World J Gastrointest Surg. 2024 Jun 27;16(6):1835-1844. doi: 10.4240/wjgs.v16.i6.1835. World J Gastrointest Surg. 2024. PMID: 38983343 Free PMC article. - Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000.
Taida T, Ohta Y, Kato J, Ogasawara S, Ohyama Y, Mamiya Y, Nakazawa H, Horio R, Goto C, Takahashi S, Kurosugi A, Sonoda M, Shiratori W, Kaneko T, Yokoyama Y, Akizue N, Iino Y, Kumagai J, Ishigami H, Koseki H, Okimoto K, Saito K, Saito M, Matsumura T, Nakagawa T, Okabe S, Saito H, Kato K, Uehara H, Mizumoto H, Koma Y, Azemoto R, Ito K, Kamezaki H, Mandai Y, Masuya Y, Fukuda Y, Kitsukawa Y, Shimura H, Tsuyuguchi T, Kato N. Taida T, et al. Sci Rep. 2023 Aug 21;13(1):13555. doi: 10.1038/s41598-023-40624-5. Sci Rep. 2023. PMID: 37604846 Free PMC article. - Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.
Kim ES, Kang B. Kim ES, et al. World J Gastroenterol. 2023 May 14;29(18):2784-2797. doi: 10.3748/wjg.v29.i18.2784. World J Gastroenterol. 2023. PMID: 37274072 Free PMC article. Review. - Autologous Fat Grafting: an Emerging Treatment Option for Complex Anal Fistulas.
Huang EY, Zhao B, Llaneras J, Liu S, Stringfield SB, Abbadessa B, Lopez NE, Ramamoorthy SL, Parry LA, Gosman AA, Dobke M, Eisenstein S. Huang EY, et al. J Gastrointest Surg. 2023 Jul;27(7):1445-1453. doi: 10.1007/s11605-023-05719-4. Epub 2023 Jun 2. J Gastrointest Surg. 2023. PMID: 37268827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical